Novartis Canada Receives Positive INESSS Recommendation for Kisqali Reimbursement

Novartis Canada has received a positive recommendation from INESSS for the public reimbursement of Kisqali for adult patients with stage II or III HR+/HER2- early breast cancer at high risk of recurrence. This follows a resubmission after an initial assessment that limited the eligible patient population. Clinical trials indicated that Kisqali reduces the risk of recurrence by 28% in a broad high-risk population, and Novartis plans to collaborate with public payers to ensure equitable access to this treatment.